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Electroretinography Reveals 
Difference in Cone Function 
between Syndromic and 
Nonsyndromic USH2A Patients
Jesse D. Sengillo1,2,3, Thiago Cabral1,2,4,5, Kaspar Schuerch1,2, Jimmy Duong6, Winston Lee1,2, 
Katherine Boudreault1,2,7, Yu Xu  8, Sally Justus1,2, Janet R. Sparrow2,9, Vinit B. Mahajan10 & 
Stephen H. Tsang1,2,9
Usher syndrome is an inherited and irreversible disease that manifests as retinitis pigmentosa (RP) and 
bilateral neurosensory hearing loss. Mutations in Usherin 2A (USH2A) are not only a frequent cause of 
Usher syndrome, but also nonsyndromic RP. Although gene- and cell-based therapies are on the horizon 
for RP and Usher syndrome, studies characterizing natural disease are lacking. In this retrospective 
analysis, retinal function of USH2A patients was quantified with electroretinography. Both groups 
had markedly reduced rod and cone responses, but nonsyndromic USH2A patients had 30 Hz-flicker 
electroretinogram amplitudes that were significantly higher than syndromic patients, suggesting 
superior residual cone function. There was a tendency for Usher syndrome patients to have a higher 
distribution of severe mutations, and alleles in this group had a higher odds of containing nonsense or 
frame-shift mutations. These data suggest that the previously reported severe visual phenotype seen in 
syndromic USH2A patients could relate to a greater extent of cone dysfunction. Additionally, a genetic 
threshold may exist where mutation burden relates to visual phenotype and the presence of hearing 
deficits. The auditory phenotype and allelic hierarchy observed among patients should be considered in 
prospective studies of disease progression and during enrollment for future clinical trials.
Usher syndrome is an inherited autosomal recessive condition affecting both hearing and vision, specifically 
manifesting as retinitis pigmentosa (RP) and bilateral neurosensory hearing loss1–4. It is the most common cause 
of deaf-blindness and currently irreversible. The retinal phenotype is characterized by night-blindness, a con-
stricting visual field, and classic pigmentary degeneration seen on imaging2, 5, 6. Usher syndrome is categorized 
clinically into three types (Usher syndrome types 1–3) based predominantly on the onset and progression of 
hearing loss. Usher syndrome type 1 typically exhibits congenital hearing loss, childhood-onset RP, and possible 
vestibular dysfunction. Usher syndrome type 2 is characterized by mild, non-progressive hearing loss and early 
adulthood-onset of RP. Usher syndrome type 3 is the rarest, typically manifesting with progressive hearing loss, 
early-onset RP, and sporadic vestibular dysfunction7, 8. In addition to this traditional classification, the diagnosis 
can be refined with genetic testing, as mutations in at least 13 genes are known to cause Usher syndrome9. These 
genes are typically involved in ciliary transport or scaffolding proteins important for cellular structure and mor-
phology5, 10–15.
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Previously, Usher syndrome was thought to affect approximately 1 in 25,000 individuals, but recent epide-
miologic data suggest a higher prevalence16. This could be due in part to cases in which there is a subtle hearing 
phenotype, resulting in an incomplete diagnosis of isolated RP. Interestingly, mutations in some genes leading to 
Usher syndrome can also manifest as nonsyndromic RP (NSRP) in other individuals, with mutations in Usherin 
2A (USH2A) being a frequent cause of both17–23. Recently, a multi-center analysis of a large USH2A patient cohort 
found different visual outcomes in patients with Usher syndrome compared to NSRP24. Syndromic patients 
tended to exhibit worse visual outcomes as measured by subjective tests of visual function and harbored a higher 
proportion of truncating mutations. Another study also assessed syndromic and nonsyndromic USH2A patients 
but found no difference in retinal disease progression when comparing patients with the p.(Cys759Phe) amino 
acid substitution in USH2A, which is associated with NSRP, to patients with a p.(Glu767Serfs*21) frameshift in 
USH2A, which is implicated in Usher syndrome6. Differences in statistical modeling of progression, follow-up 
time, and the genotypes of interest in each study may account for the differing results, highlighting the need 
for further investigation. Assessing functional outcomes in syndromic and nonsyndromic USH2A patients is 
essential for patient management and counseling. Furthermore, understanding natural disease is necessary for 
future clinical trials so physicians can conclude if treatments are efficacious and which patients are most likely to 
benefit7, 25.
The present study sought to elucidate differences in cone function between Usher syndrome and NSRP due to 
mutations in the same USH2A gene. Patients were examined in a single electrophysiology clinic using objective 
visual function data, specifically the 30 Hz-flicker full-field electroretinogram (ffERG). The 30 Hz-flicker ffERG 
is a commonly used outcome measure of visual function and prognosis in RP patients26–31. This particular ffERG 
measures cone function by exposing the patient to a light stimulus at a rate of 30 flashes per second after the ret-
ina is bleached to suppress rod responses, resulting in a predominantly L- and M-cone response. While the rod 
response aids in diagnosis and is typically severely diminished or completely extinguished in Usher syndrome and 
RP, the 30 Hz-flicker is useful for assessing retinal function in clinical practice, as cones are affected later in the 
disease course26, 27, 31, 32. The mutation spectrum was also assessed in this cohort of USH2A patients and compared 
to the findings of previous studies.
Results
Clinical data. A total of 10 patients were diagnosed with Usher syndrome type IIA and 10 patients were diag-
nosed with recessive NSRP based on clinical history, family history, dilated fundus exam, presence or absence of 
subjective hearing loss, and genetic confirmation of two or more USH2A mutations. The diagnosis was supported 
by multimodal retinal imaging (Fig. 1) and/or ffERG scotopic b-wave responses that were decreased to a greater 
extent than photopic responses, indicative of a rod-cone dystrophy. Clinical and genetic findings of the cohort are 
provided in Tables 1 and 2. The average age of the Usher syndrome group was 33 (n = 10) compared to 44 (n = 10) 
in the NSRP group (p = 0.16). Four eyes had best-corrected visual acuity (BCVA) of 20/100 or worse in Usher 
syndrome patients. In NSRP patients, one eye was less than 20/100, which was in the context of cystoid macular 
edema (CME). Three of ten Usher syndrome patients had a bulls-eye pattern of macular atrophy or significant 
maculopathy in both eyes. One NSRP patient had a bulls-eye pattern of atrophy bilaterally. On fundoscopy, nine 
Usher syndrome patients had evident intraretinal pigment migration. In the youngest patient (P10), no intraret-
inal pigment migration was observed. In the NSRP group, seven patients had intraretinal pigment migration. No 
patient showed evidence of CME on SD-OCT in either eye of Usher syndrome patients, compared to three NSRP 
patients. Two patients (P8 and P14) underwent previous audiometry for which P8 (Usher syndrome) was found 
to have bilateral neurosensory hearing loss. P14 (NSRP) underwent audiometry to screen for hearing loss after 
receiving results of genetic testing, which was in the normal range.
Electrophysiology. Results of ffERG testing are presented in Table 3. Eight patients in each group under-
went electroretinography. NSRP patients had mean 30 Hz-flicker amplitudes of 17.04 ± 16.7 μV (mean ± SD), 
compared to Usher syndrome patients, 2.13 ± 1.64 μV (Fig. 2). 30 Hz-flicker amplitudes were compared between 
groups using the Wilcoxon rank-sum test (p = 0.0023). Seven of eight patients in the Usher syndrome group 
required Burien-Allen (BA) contact lens electrodes compared to three of eight NSRP patients. All others used 
Dawson, Trick, and Litzkow (DTL) recording electrodes. Of the 10 total patients whose recordings were per-
formed with BA contact lens electrodes, four (P3, P4, P6, P8) also had prior DTL recordings performed during 
the same visit; all four DTL recordings were nondetectable. Five of eight Usher syndrome patients had an implicit 
time delay in 30 Hz-flicker recordings compared to all NSRP patients (p = 0.20). Scotopic b-wave amplitudes were 
recorded in a total of 12 patients (24 eyes). Scotopic b-waves were extinguished in all 10 eyes of Usher syndrome 
patients and 10 of 14 eyes of NSRP patients.
Genetic analyses. The genetic profile of all patients are provided in Table 2, and each USH2A mutation 
identified in the cohort is tabulated in Supplemental Table 1. All patients had family histories consistent with an 
autosomal recessive inheritance pattern. No patients in this cohort were related to each other. P19 reported a fam-
ily history of parental consanguinity. The distribution of severe mutations was assessed between groups. A severe 
mutation was defined as a nonsense mutation or an indel (insertion or deletion) resulting in an out-of-frameshift. 
The percentage of Usher syndrome patients having at least one severe mutation was 70% compared to 30% of 
NSRP patients (p = 0.089). In the Usher syndrome group, 45% (9/20) of alleles had a nonsense mutation or an 
indel resulting in an out-of-frameshift compared to 15% (3/20) of NSRP patients. The odds ratio for an allele 
containing a frameshift or nonsense mutation in the Usher syndrome group compared to the NSRP group was 4.6 
(confidence interval: 1.1 to 20, p = 0.039). Two patients in the Usher syndrome group harbored two truncating 
alleles compared to no patients in the NSRP group. Mutations were known to be in trans or homozygous in 5 of 
10 Usher syndrome patients and 6 of 10 NSRP patients. The phase of the two USH2A mutations was unknown in 
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the remaining patients. A 27 base-pair deletion was identified in P10 (Usher syndrome), which included the loss 
of a splice-site acceptor. As it is not clear if this allele is affected more by aberrant splicing or a frameshift, it was 
not counted as severe to maintain a conservative analysis. A homozygous, in-frame duplication was identified in 
P19 (NSRP) and thus not considered severe based on our criteria, as the amino acid reading frame is unaffected. 
One of 10 patients in the Usher syndrome group and three of 10 patients in the NSRP group harbored at least one 
variant affecting splicing. One patient (P12) was identified to have three variants in USH2A, in which the variant 
affecting splicing was found to be in trans to the two missense variants.
Structural measurements. Short wavelength autofluorescent (SW-AF) and spectral-domain optical coher-
ence tomography (SD-OCT) imaging were obtained for all patients. Four patients (P7, P9, P13, P20) had bilateral 
Figure 1. Retinal imaging of a patient with NSRP due to mutations in USH2A compared to a healthy 
individual. Color fundus photo of the posterior pole of a healthy individual (a) compared to a patient (P18) with 
NSRP (b), showing extensive intraretinal pigment migration observed temporally. SW-AF imaging reveals a 
characteristic foveal autofluorescent ring in P18 (d), which is absent in the healthy individual (c). SD-OCT of a 
healthy individual shows intact retinal structure (e, top) compared to P18 (e, bottom). Note the thinning of outer 
retinal layers in the periphery and the sparing of the ellipsoid zone in the central macula in P18.
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advanced disease, rendering the ellipsoid zone (EZ) line length and AF ring diameters unmeasurable; the left eye 
of one patient (P4) had a macular hole that prevented accurate EZ-line and ring visualization. One patient (P17) 
had a granular AF ring that was not quantifiable. CME was observed on SD-OCT for three patients (P15, P18, 
P20) but did obscure the EZ-line. No patients warranted exclusion due to poor imaging quality. For all eyes with 
an AF ring, it was visible within the central 30 degrees of the retina. AF ring diameters were generally symmetri-
cal between eyes, and 15 of 16 patients had horizontal diameters that were larger than vertical diameters. Mean 
EZ-line length between both eyes were 2425 µm for Usher syndrome patients and 3145 µm for NSRP patients 
(p = 0.38); Usher syndrome patients had mean horizontal and vertical ring diameters of 3633 μm and 3044 μm, 
respectively, compared to a horizontal diameter of 3915 μm (p = 0.71) and vertical diameter of 3101 μm (p = 0.94) 
in NSRP patients (Fig. 3).
Case Study. A 41-year-old female with RP and two confirmed pathogenic USH2A mutations, c.10073G > A 
and c.920_923dupGCCA, did not have an auditory phenotype documented on previous intake forms or clinic 
notes. As subjective hearing loss could not be confirmed, this patient was excluded from analyses (see methods). 
Of interest, she did undergo previous audiometry for the work-up of tinnitus, which was found to be within the 
normal range for all tested frequencies. FfERG scotopic b-waves and 30 Hz-flicker amplitudes for this patient were 
higher than all patients in the cohort (Supplemental Table 2). Multimodal retinal imaging was performed in this 
patient, which was consistent with RP (Supplemental Fig. 2).
Discussion
Usher syndrome presents with considerable genetic and phenotypic variability between individuals. Mutations 
in at least 13 genes are known to cause Usher syndrome but may manifest as a different clinical entity in other 
patients. In addition to USH2A, mutations in CLRN1 are also known to cause both Usher syndrome and NSRP33. 
Furthermore, a longer list of genes are associated with both Usher syndrome and nonsyndromic recessive deaf-
ness (CDH23, CIB2, DFNB31, MYO7A, PCDH15, and USH1C)5. In these cases, differences in the mutational 
spectrum may relate to disease manifestation. For MYO7A and CDH23, truncating mutations are reported to be 
more commonly associated with Usher syndrome, while ‘leaky’ splice site and missense mutations manifest as 
nonsyndromic deafness34, 35. RP with hearing deficits have also been reported in the context of X-linked RPGR 
mutations, albeit less frequently36. The present study focused specifically on Usher syndrome and recessive NSRP 
due to mutations in USH2A, and is first to elucidate differences in cone function between these groups.
Overall, our data suggest that patients with Usher syndrome due to USH2A mutations have a more attenuated 
30 Hz-flicker response compared to their NSRP counterparts (Fig. 2). NSRP patients in this retrospective analysis 
had a mean 30 Hz-flicker amplitude of 17 µV at an average age of 44 years old (n = 8). Usher syndrome patients in 
our cohort had inferior cone function with a mean 30 Hz-flicker amplitude of 2.1 μV at a younger average age of 33 
years old (n = 8). 30 Hz-flicker ffERGs are a useful outcome measure to assess, as scotopic responses are affected 
earlier and often already extinguished in both RP and Usher syndrome at presentation. Photopic 30 Hz-flicker 
response is an outcome in previous landmark clinical trials assessing the efficacy of dietary supplements for RP27–29  
and published actuarial tables provide conversions for 30 Hz-flicker amplitudes into prognoses for patient 
counseling26. Together, these data suggest that the presence of subjective hearing loss in USH2A patients may 
ID Gender Age BCVA (OD) BCVA (OS) Pigment CME (OD, OS) Comments
Syndromic
P1 M 25 20/20 20/20 + −
P2 M 17 20/20 20/20 + −
P3 M 45 20/20 20/50 + −
P4 F 24 20/20 20/400 + − Macular Hole OS
P5 F 28 20/20 20/20 + −
P6 F 24 20/30 20/50 + −
P7 M 59 20/125 20/LP + − Bulls-eye OU
P8 F 36 20/25 20/40 + − Bulls-eye OU
P9 M 57 20/100 20/80 + − Maculopathy
P10 M 19 20/60 20/40 − −
Nonsyndromic
P11 F 30 20/20 20/20 + −
P12 M 16 20/20 20/20 − −
P13 M 68 20/40 20/60 − − Bulls-eye OU
P14 F 31 20/20 20/20 + −
P15 F 25 20/30 20/25 + +, +
P16 M 56 20/50 20/25 + −
P17 F 57 20/20 20/20 + −
P18 F 52 20/30 20/25 + +, −
P19 M 50 20/25 20/20 − −
P20 M 55 20/200 20/80 + +, −
Table 1. Clinical Characteristics of USH2A Patients. BCVA, best-corrected visual acuity; OD, right eye; OS, left 
eye; OU, both eyes; CME, cystoid macular edema.
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be predictive of worse cone function and thus visual phenotype. Interestingly, these large differences in retinal 
function did not corroborate structural measurements obtained from multimodal imaging in both groups, which 
would have been predicted based on the stark difference in 30 Hz-flicker amplitudes (Fig. 3). Future comparisons 
may require more subjects to detect a potential statistical difference. Alternatively, the difference in ERG ampli-
tudes may reflect the number of healthy cone photoreceptors in the peripheral retina, as an ERG represents an 
average of the entire fundus. In contrast, structural measurements in this study were within the macula, which 
is affected later in the disease course. Lastly, functional loss precedes structural changes, hence an ERG is a more 
sensitive test to detect changes in the retina. As a result, structural measurements for both groups may be assessed 
more effectively as a progression rate over a longitudinal follow-up, as opposed to in cross-section.
The Usher syndrome group was more likely to be enriched with disease alleles containing either an indel or 
nonsense mutation, which generally has a more deleterious effect on protein structure (Table 1). Allelic hierarchy 
has been reported previously and was confirmed in this study19. It is possible that a genetic threshold exists in 
which the combined burden of the two alleles is severe enough to cause hearing loss in addition to the retinal 
phenotype. Alternatively, differential disruption of USH2A isoforms or their expression patterns in photoreceptor 
ID Gender Age USH2A mutation Protein Change Segregation
Syndromic
P1 M 25
c.1724G > A p.(Cys575Tyr)
—
c.2299delG p.(Glu767Serfs*21)
P2 M 17
c.3713C > G p.(Thr1238Arg)
—
c.9459C > A p.(Cys3153*)
P3 M 45
c.8442_8443insT p.(Thr2815Tyrfs*20)
—
c.1000C > T p.(Arg334Trp)
P4 F 24
c.11918delC p.(Ala3973Valfs*11)
In trans
c.10712C > T p.(Thr3571Met)
P5 F 28
c.2299delG p.(Glu767Serfs*21)
Homozygous
c.2299delG p.(Glu767Serfs*21)
P6 F 24
c.13112_13115delAAAT p.(Gln4371Argfs*19)
In trans
c.13943delG p.(Gly4648Aspfs*30)
P7 M 59
c10712C > T p.(Thr3571Met)
Homo
c10712C > T p.(Thr3571Met)
P8 F 36
c10712C > T p.(Thr3571Met)
In trans
c.4711G > C p.(Ala1571Pro)
P9 M 57
c.2299delG p.(Glu767Serfs*21)
—
c.12574C > T p.(Arg4192Cys)
P10 M 19
c.15520-22_15524del27 p.(?)
—
c.6049 + 2T > G p.(?)
Nonsyndromic
P11 F 30
c.9676C > T p.(Arg3226*)
—
c.1478A > G p.(Tyr493Cys)
P12 M 16
c.4251 + 1G > Aǂ p.(?)
ǂIn transc.13223T > C p.(Val4408Ala)
c.13231C > G p.(Leu4411Val)
P13 M 68
c.2276G > T p.(Cys759Phe)
Homozygous
c.2276G > T p.(Cys759Phe)
P14 F 31
c.10073 G > A p.(Cys3358Tyr)
—
c.10759C > T p.(Gln3587*)
P15 F 25
c.13010C > T p.(Thr4337Met)
—
c.9740-1G > T p.(?)
P16 M 55
c.10073G > A p.(Cys3358Tyr)
Homozygous
c.10073G > A p.(Cys3358Tyr)
P17 F 57
c.14287G > A p.(Tyr493Cys)
In trans
c.3476C > T p.(Pro1159Leu)
P18 F 52
c.895delC p.(Gln299Asnfs*37)
—
c.5848A > G p.(Thr1950Ala)
P19 M 50
c.13491_13499dupTACTCTCAC p.(Thr4498_Thr4500dup)
Homozygous
c.13491_13499dupTACTCTCAC p.(Thr4498_Thr4500dup)
P20 M 55
c.12575G > A p.(Arg4192His)
In trans
c.8682-9A > G p.(?)
Table 2. Genetic Profile of USH2A Patients.
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and inner ear cells may account for variable hearing deficits. The genetic heterogeneity and frequent occurrence 
of compound heterozygous mutations in USH2A patients, however, make it difficult to confirm this hypothesis.
In our cohort of 20 patients, exactly 31 unique disease-causing variants were identified in USH2A. Of these, 
the most common variants were c.2299delG, c.10073G > A, and c.10712C > T. The c.2299delG variant is the 
most frequent disease-causing variant of Usher syndrome in multiple studies37–39, and was not found in the NSRP 
group. c.10712C > T mutations were only identified in Usher syndrome patients in this cohort, and previous 
studies have also associated this particular variant with RP and an auditory phenotype19. This missense mutation 
causes the reading frame to be interrupted by a premature STOP codon; mRNA produced might be targeted for 
nonsense-mediated decay. Interestingly, Lenassi et al. found the c.10073G > A, c.2276G > T, and c.12575G > A 
mutations to be ‘retinal disease specific’ and hypothesized the presence of one of these mutations leads to a non-
syndromic manifestation, largely independent of the second mutation19. Our mutational analysis found this to be 
possible. P13 and P16, both NSRP, harbored homozygous c.10073G > A and c.2276G > T variants, respectively. 
Similarly, the presented case study featured a patient with the ‘retina-specific’ c.10073G > A mutation17, 19, 21. This 
patient had a normal audiogram across all frequencies in addition to scotopic B-wave and 30 Hz-flicker ampli-
tudes that were higher than all patients in the cohort.
There are previous studies with contrasting findings. Sandberg et al. compared patients with the p.(Cys759Phe) 
amino acid substitution in USH2A, which is known to cause NSRP, with patients that had a p.(Glu767fs*21) 
truncating mutation, known to cause Usher syndrome. No differences in disease progression were detected6. Our 
cohort observed only one patient (P13, NSRP) with the p.(Cys759Phe) substitution in USH2A and three patients 
(P1, P5, P9) with the p.(Glu767fs*21) truncating mutation, preventing a meaningful comparison within this 
study. However, conclusions from the present study are in accordance with the previously mentioned multi-center 
cohort study performed in Europe that found Usher syndrome patients to be diagnosed earlier, became visually 
impaired sooner by subjective functional testing, and have a higher frequency of truncating mutations compared 
to NSRP patients24. Visual prognoses were determined in their cohort with visual acuity and field measurements, 
which were superior in NSRP. Our retrospective analysis confirms a severe visual phenotype in Usher syndrome, 
elucidates differences in visual function with an objective test, and is the first to document differences in ffERG 
cone responses between these populations, an important index in RP research and clinical practice.
There are limitations to our study. Patients underwent ffERG testing with BA contact lens or DTL recording 
electrodes. Four Usher syndrome patients in this cohort underwent recordings with both DTL-recording elec-
trodes and BA contact lenses in the same visit, with undetectable waveforms in the former. The increased use of 
BA contact lens electrodes in the Usher syndrome group likely decreased the potential difference between groups, 
which was still statistically significant. Prospective investigations and clinical trials would benefit from the use of a 
single type of recording electrode to compare cone function over time. Another limitation is the aforementioned 
genetic heterogeneity of Usher syndrome and RP, which lends smaller cohorts difficult to interpret. Of the 20 
patients in this cohort, 4 were homozygous for USH2A mutations. In compound heterozygotes it is difficult to 
parse the contribution of a specific mutation to disease phenotype without a larger cohort. Lastly, using subjective 
hearing loss to diagnosis either Usher syndrome or NSRP likely leads to misclassification of patients with a subtle 
ID
Scotopic B-wave 
Amplitude (µv)
30 Hz Flicker 
Amplitudes (µv)
30 Hz Flicker 
Implicit Time (ms)
ElectrodeOD OS OD OS OD OS
Syndromic
P1 — — 2.4 2.3 19 21 ba
P2 ext ext 1.0 1.2 38d 33d ba
P3 ext ext 1.7 2.7 28d 31d ba
P4 ext ext 1.7 6.5 34d 33d ba
P5 ext ext 2.8 7.2 28 28 dtl
P6 ext ext 0.7 0.4 33d 32d ba
P7 — — 1.3 0.7 28 27 ba
P8 — — 0.8 0.8 27d 28d ba
P9 — — — — — — —
P10 — — — — — — —
Nonsyndromic
P11 ext ext 12.9 15.7 40d 39d dtl
P12 ext ext 5.0 4.2 44d 45d dtl
P13 20.3 26.8 7.3 11.6 40d 41d dtl
P14 ext ext 22.6 22.0 42d 43d dtl
P15 — — 19.2 24.6 30d 30d ba
P16 109.1 141.0 43.5 64.6 31d 30d dtl
P17 ext ext 5.1 9.0 33d 33d ba
P18 ext ext 3.0 2.4 27 31d ba
P19 — — — — — — —
P20 — — — — – — —
Table 3. Electroretinography of USH2A Patients. OD, right eye; OS, left eye; ext, extinguished; −, not 
performed; ba, Burian-Allen contact lens electrode; dtl, DTL recording electrode; ddelayed.
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hearing phenotype that is undetectable to the patient. However, using subjective hearing loss as a criterion was 
useful in stratifying differences in auditory phenotype and can guide genetic screening and counseling. Still, a 
more sophisticated and quantifiable measure of hearing loss may reveal other correlations between particular 
mutations and auditory or visual manifestations. Future investigations should consider comparing visual out-
comes to a quantifiable measure of auditory function, such as a standardized audiometry.
There is currently no cure for Usher syndrome. Standard management typically involves monitoring com-
plications of RP and providing assistive hearing devices such as hearing aids or cochlear implants40. However, 
after previous demonstration of safety and efficacy in macaques, clinical trials for Usher syndrome type IB are 
underway that involve subretinal administration of UshStat® (EIAV-CMV-MYO7A) (NCT01505062)41. Recently, 
a preclinical anti-sense oligonucleotide has also shown promise in an Usher syndrome type 1C mouse model 
after being identified in an in vitro screen. By blocking an aberrant splice site, vestibular and auditory rescue is 
achieved in this model42. Specific to USH2A, investigators corrected the effects of a deep intronic mutation in 
patient-derived fibroblasts43. With gene- and cell-based therapies becoming a reality, studies characterizing nat-
ural disease become essential for assessing treatment efficacy. This study not only provides objective functional 
data comparing retinal function between Usher syndrome and NSRP caused by mutations in the same gene, but 
may also prove useful for retina specialists counseling USH2A patients.
Methods
Subjects. This retrospective analysis was approved by the Edward S. Harkness Eye Institute and Columbia 
University Internal Review Boards and adhered to the tenets of the Declaration of Helsinki. The data presented 
in this study, including images and genetic testing results, are not identifiable to individual patients. Informed 
Figure 2. Differences in 30 Hz flicker electroretinogram between syndromic and nonsyndromic USH2A 
patients. (a) Modified box-and-whisker plots with individual patient data points reveal a statistically significant 
difference in 30 Hz-flicker amplitudes between Usher syndrome and NSRP patients. Representative 30 Hz-
flicker ERGs for a normal patient (b), Usher syndrome patient (P5, c), and NSRP patient (P11, d). P5 had the 
highest average 30 Hz-flicker amplitude among Usher syndrome patients; P11 had a 30 Hz-flicker amplitude 
average nearest to the median of the NSRP group. Circles, individual patient data points; black lines, right eye; 
purple lines, left eye; dashed lines in (b–d), illustrate amplitude difference between peak and trough.
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consent for participation was obtained as outlined in the Columbia University Medical Center IRB-approved 
protocol, AAAR0284. Patients diagnosed with Usher syndrome or NSRP at the Harkness Eye Institute electrodi-
agnostics clinic were considered for inclusion in electroretinogram or mutational analyses based upon: (1) if they 
harbored at least two pathogenic or likely pathogenic USH2A variants and (2) had prior documentation of the 
presence or absence of subjective hearing loss on clinic notes or patient intake forms. It is important to note that 
all patients in the NSRP group reported no hearing loss on an intake form or during the clinic visit as per the phy-
sician note, meaning the auditory phenotype was not assumed to be normal if it was not stated explicitly. Twenty-
seven patients presenting to clinic between 2010 and 2016 were found to have at least two USH2A mutations. Out 
of the 27 patients, seven were excluded from analyses for the following reasons: USH2A variants occurred in cis 
(one patient); two USH2A variants were reported as benign (one patient); other identified gene variants could rea-
sonably account for disease phenotype with no accompanying co-segregation analysis (three patients); there was a 
confounding history of subjective hearing loss, which is the independent variable in each analysis performed (one 
patient); or there was no documentation of the presence or absence of hearing loss (one patient). The 20 included 
USH2A patients were analyzed in two groups, Usher syndrome (n = 10) and NSRP (n = 10). Multimodal imaging 
was acquired in all patients and a total of 16 patients underwent ffERG testing.
Genetic analyses. For all patients, DNA was isolated from whole blood lymphocytes for sequencing. Most 
patients (15 of 20) had genetic testing for a panel of genes known to cause Usher syndrome or RP by next gen-
eration sequencing and subsequent confirmation with Sanger sequencing at the Casey Eye Institute Diagnostic 
Laboratory (Portland, Oregon), Molecular Vision Laboratory (Hillsboro, Oregon), or Columbia University 
Figure 3. Comparison of structural measurements on retinal imaging between syndromic and nonsyndromic 
USH2A patients. Mean horizontal and vertical autofluorescent ring diameters measured on SW-AF (a) and 
ellipsoid zone line length measured on SD-OCT (b) were compared between syndromic and non-syndromic 
USH2A patients (c). Circles, individual patient data points; dashed lines, group mean.
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Medical Center Pathology Department (New York, NY). Whole exome sequencing was performed on three 
patients by the Columbia University Medical Center Pathology Department (New York, NY). The remaining 
two patients had genetic testing performed at the National Institute on Deafness and Other Communication 
Disorders (Bethesda, Maryland) and the John and Marcia Carver Nonprofit Genetic Testing Laboratory (Iowa 
City, IA). USH2A variants were analyzed by Alamut software version 2.2 (Interactive Biosoftware, Rouen, France).
Electroretinography. FfERGs were acquired with the Diagnosys Espion Electrophysiology System 
(Diagnosys LLC, Lowell, MA, USA) from both eyes using DTL recording electrodes in accordance to the 
International Society for Clinical Electrophysiology of Vision (ISCEV) standards in scotopic and photopic 
states44, 45. When the 30 Hz-flicker amplitudes were lower than five microvolts or predicted to be lower than five 
microvolts based on exam, Burian-Allen contact lens electrodes were used to record the 30 Hz-flicker responses 
that are subsequently processed through narrow band-passed filtering with computed averaging26, 44, 46, 47. The 
amplitudes obtained from both eyes were measured by a single user with Espion V6.0.56 software (Diagnosys 
LLC, Lowell, MA, USA), which calculates the amplitude from trough to peak of the first visible waveform, as 
performed previously46, 48–50. Amplitudes of both eyes were averaged and compared between the two groups.
Imaging. Fundus SW-AF and SD-OCT images were obtained in all patients after dilation using Spectralis 
HRA + OCT device (Heidelberg Engineering, Heidelberg, Germany). SW-AF images were acquired using a 
30-degree field of view with 1536 × 1536 pixel resolution. SW-AF imaging utilized a 521nm barrier filter and 
486nm wavelength stimulus. The external horizontal and vertical ring diameter of SW-AF imaging was measured 
manually using Spectralis software (Heidelberg Eye explorer, software version 1.9.10, Heidelberg Engineering, 
Heidelberg, Germany). SD-OCT was obtained with an 870nm light source and automatic real-time registration 
of the fundus infrared reflectance image. Horizontal scans (high resolution mode, 9mm, ART, average of a mini-
mum of 50 images) through the fovea provided a view of the EZ-line and was measured manually using Spectralis 
software. All measurements were obtained by a single observer (T.C), who was masked to whether the patient was 
in the Usher syndrome or NSRP group.
Statistical analyses. All statistical analyses were performed using Stata/IC software version 13.0 (StataCorp 
LLC, College Station, Texas). 30 Hz-flicker ffERG amplitudes were compared between Usher syndrome and NSRP 
patients using a Wilcoxon-rank sum test. Right and left eyes were averaged prior to statistical analysis. To com-
pare the distribution of patients harboring at least one frameshift (indel) or nonsense mutation, a Fisher’s exact 
test was used (Table 4, row 4). To account for a possible correlation of observations from the same subject, the 
odds of having either an indel or nonsense mutation in one allele was compared between both groups by fitting 
logistic regression models using generalized estimating equations. In this case, the outcome variable was whether 
an allele had either a nonsense mutation or an indel resulting in an out-of-frame shift (Table 4, row 5). Structural 
measurements acquired from SD-OCT (EZ-line length) and SW-AF imaging (horizontal and vertical ring diame-
ters) were compared using a two-tailed Student’s t test with unequal variance. Measurements for the right and left 
eye were averaged prior to comparing groups for all indices. A p value less than 0.05 was considered statistically 
significant in all results reported. All values are expressed as mean ± standard deviation (SD) unless otherwise 
indicated.
Data Availability. All data generated or analyzed for this study are included in this published article.
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